English Overview
Prof. Andreas Hartkopf (DE), Dr. Tal Sella (IL), and Prof. Valentina Guarneri (IT), with Prof. Qiang Liu (Chair session 1) and Monique Coersmeyer (Chair sessions 2 and 3) will participate in the meeting to discuss Optimising Treatment Approaches for HR+, HER2- EBC. The panel discussion will cover identifying patients who are at high-risk of recurrence, different treatment approaches and insights into the management of side effects to improve adherence.
This Activity for
- Resident / Fellow
- Physician
What I will learn?
• Share data on the latest data for abemaciclib for patients with HR+ HER2-breast cancer in the EBC and MBC setting and discuss the impact of this data in clinical practice. It will be an expert MDT discussion on the identification of high-risk HR+/HER2- EBC and MBC and includes; Multidisciplinary In-Depth Insights, EBC Patient Case Study, MBC Patient Case Study, Panel Discussions and Live Q&A
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
BC TALKS: “Optimising Treatment approaches for HR+/HER2- Early Breast Cancer” Certificate
Certificate |
Certificate | Free |
VAT 15% Included
